Recce Pharma heading closer to full efficacy data for flagship R327
Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial has been dosed.
Last update - 16.20pm 15/05/2024 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 14.0¢ | Day High | 14.0¢ | Day Low | 13.0¢ | |||
| Daily Volume | 170000 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 1 | 13.0¢ | 20167 | 1 | 14.5¢ | 12564 | |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
-0.010(7.14%) |
Mkt cap ! $14.19M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.0¢ | 13.0¢ | $23.40K | 170K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20167 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 12564 | 1 |
View Market Depth
| Last trade - 15.16pm 15/05/2024 (20 minute delay) ? |
| BNZ (ASX) Chart |
